1,017 reports of this reaction
4.5% of all ALTEPLASE reports
#4 most reported adverse reaction
GINGIVAL BLEEDING is the #4 most commonly reported adverse reaction for ALTEPLASE, manufactured by Genentech, Inc.. There are 1,017 FDA adverse event reports linking ALTEPLASE to GINGIVAL BLEEDING. This represents approximately 4.5% of all 22,483 adverse event reports for this drug.
Patients taking ALTEPLASE who experience gingival bleeding should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GINGIVAL BLEEDING is moderately reported among ALTEPLASE users, representing a notable but not dominant share of adverse events.
In addition to gingival bleeding, the following adverse reactions have been reported for ALTEPLASE:
The following drugs have also been linked to gingival bleeding in FDA adverse event reports:
GINGIVAL BLEEDING has been reported as an adverse event in 1,017 FDA reports for ALTEPLASE. This does not prove causation, but indicates an association observed in post-market surveillance data.
GINGIVAL BLEEDING accounts for approximately 4.5% of all adverse event reports for ALTEPLASE, making it a notable side effect.
If you experience gingival bleeding while taking ALTEPLASE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.